@article {970,
	title = {Harvesting peripheral blood progenitor cells from healthy donors: retrospective comparison of filgrastim and lenograstim},
	journal = {Journal of Clinical Apheresis},
	volume = {20},
	year = {2005},
	note = {HPC Martino M Console G Irrera G Callea I Condemi A Dattola A Messina G Pontari A Pucci G Furl{\`o} G Bresolin G Iacopino P Morabito F Comparative Study Journal Article Research Support, Non-U.S. Gov{\textquoteright}t},
	month = {Oct},
	pages = {129 - 36},
	abstract = {Mobilization of CD34+ into peripheral blood is attained by either glycosylated (lenograstim) or non-glycosylated recombinant G-CSF (filgrastim). 101 donors, 57 males, median age 42 years (range 16-63) entered this retrospective study. Group I (55 cases) received filgrastim and group II lenograstim subcutaneously for 5-6 days. The peak number of CD34+ cells/microl blood observed on day 4 and 5 was not significantly different in the two groups. No differences were shown in terms of both circulating CFU-GM at the time of harvesting and CD34+ target of collection. The most frequent side effects were bone pain (18.2\% grade I; 36.4\% grade II, 7.3\% grade III), headache (18.2\%), nausea (9.1\%), fever (5.5\%) and a mild splenomegaly (> 2 cm) (5.5\%) in filgrastim group, and bone pain (37.0\% grade I, 26.1\% grade II, 2.2\% grade III), headache (17.4\%), nausea (15.2\%), fever (4.4\%) and a mild splenomegaly (4.3\%) in lenograstim group, respectively. CD34+ collection was associated with thrombocytopenia, which was not significantly different between the two groups. No donor in either group developed long-term adverse effects. We conclude that both G-CSFs are comparable in terms of CD34+ cell collection, safety and tolerability. Copyright 2005 Wiley-Liss, Inc},
	author = {Martino,Massimo and Console,Giuseppe and Irrera,Giuseppe and Callea,Ida and Condemi,Antonia and Dattola,Antonella and Messina,Giuseppe and Pontari,Antonella and Pucci,Giulia and Furlo,Giuseppe and Bresolin,Giuseppe and Iacopino,Pasquale and Morabito,Fortunato}
}
